What Are Peptides? Structure, Function, and What the Science Shows

Key Takeaways

• What they are: Short chains of amino acids linked by peptide bonds; smaller than proteins and more structurally targeted.
• Where they come from: Produced naturally by the body (endogenous); also synthesized in laboratories and found in food sources.
• In medicine: As of April 2026, dozens of peptide drugs are FDA-approved across metabolic disease, cardiovascular disease, oncology, hormone regulation, and more.
• Research stage: FDA-approved peptides have robust clinical trial evidence; research-grade peptides vary widely from animal-only data to early human trials.
• Safety framing: Safety depends primarily on whether the compound is FDA-reviewed; unregulated sources carry purity and dosing risks not present in approved medications.

What Peptides Are

A peptide is a chain of amino acids connected by covalent peptide bonds — the same chemical linkages that form proteins — but shorter, typically defined as 2 to 50 amino acids in length, though definitions in the literature extend the upper bound to 100 amino acids depending on the discipline. The StatPearls chapter by Forbes Kaprive and Krishnamurthy, published through the National Institutes of Health, defines peptides as short strings of 2 to 50 amino acids joined via covalent peptide bonds formed in condensation reactions, providing a standard textbook-level definition. Peptides are smaller than proteins but operate through many of the same biochemical principles. Their relative compactness allows them to act as highly specific signaling molecules rather than structural components. Apostolopoulos and colleagues, in a 2021 review in Molecules, reviewed short peptides as therapeutics across applications spanning disease treatment, vaccines, and drug delivery.

Peptide bonds and amino acid structure

Amino acids are the monomers of peptide chemistry. Each amino acid contains an amino group (NH₂) on one end, a carboxyl group (COOH) on the other, and a variable side chain that determines its individual chemical character. A peptide bond forms when the carboxyl group of one amino acid undergoes a condensation reaction with the amino group of the next, releasing a water molecule and creating a covalent amide linkage. This produces a directional chain with an N-terminus (free amino end) and a C-terminus (free carboxyl end). The sequence of amino acids — read from N-terminus to C-terminus — determines the peptide's structure and, ultimately, its biological function. Sanvictores and Farci, writing in the 2025 StatPearls chapter on protein primary structure, explain protein primary structure as the linear amino-acid sequence from which all higher-order biological activity emerges.

Peptides vs. proteins: where the line is

The boundary between a peptide and a protein is a convention, not a sharp biological distinction. Most definitions place peptides at 2 to 50 amino acids and proteins at 50 or more, with folded three-dimensional structures that enable more complex functions. The StatPearls chapter by Sanvictores and Farci frames protein primary structure as a linear polypeptide — the same chemical entity as a peptide, simply longer. Insulin illustrates the ambiguity well: at 51 amino acids across two peptide chains, it is routinely classified as a protein hormone despite falling at the boundary of the peptide size range, as Derewenda and colleagues established in their 1989 structural work on insulin's two-chain peptide architecture. GLP-1, by contrast, is 30 amino acids — unambiguously peptide-sized. The functional distinction is more useful than the size cutoff: peptides tend to act as signals that bind receptors and trigger cascades, rather than as structural scaffolds or enzymes. That signaling specificity is what enables both the therapeutic applications and physiological roles of the peptide class.

How Peptides Work in the Body

Most biologically active peptides function as signaling molecules. Their specificity comes from receptor binding: a particular peptide sequence recognizes a particular receptor, triggering a downstream cascade that produces a cellular or systemic response.

Cell signaling and receptor binding

Peptide hormones typically bind to cell-surface receptors — most commonly G protein-coupled receptors (GPCRs) — and activate intracellular signaling cascades. Posner and Laporte, in their foundational review published in Progress in Brain Research in 2010, established that peptide hormones activate cell-surface receptors to drive metabolic and proliferative responses through kinase cascades and transcription-factor activation. GLP-1 is a well-studied modern example: Holst's 2007 review in Physiological Reviews described how GLP-1 produced in intestinal L-cells binds GLP-1 receptors on pancreatic beta cells, triggering insulin secretion and glucagon suppression in a glucose-dependent manner. That receptor-specific mechanism is why GLP-1 receptor agonists can enhance insulin secretion without causing hypoglycemia at normal glucose levels — the receptor's downstream signaling is context-sensitive. Wang and colleagues, in a 2022 review in Signal Transduction and Targeted Therapy, provided a comprehensive overview of how peptide drug design leverages receptor specificity across therapeutic categories.

Endogenous peptides: what your body already makes

The human body synthesizes peptides continuously. Several are foundational to physiology:

• Insulin: A 51-amino-acid peptide hormone that regulates blood glucose by facilitating cellular glucose uptake.
• GLP-1: A 30-amino-acid incretin peptide produced in the gut that stimulates insulin release and suppresses appetite.
• Oxytocin: A 9-amino-acid neuropeptide involved in social bonding, trust, and parturition.
• Vasopressin (ADH): A 9-amino-acid peptide that regulates water reabsorption in the kidney.
• Ghrelin: A 28-amino-acid peptide produced in the stomach that stimulates growth hormone release and drives appetite.
• Glucagon: A 29-amino-acid pancreatic peptide that mobilizes glucose from glycogen stores during fasting.

Forbes's 2023 review in Vitamins and Hormones documented insulin's molecular structure and receptor-binding mechanisms in detail, illustrating how the body's own peptides inform the design of therapeutic peptide drugs developed over subsequent decades.

How the body breaks peptides down

Peptides are metabolized by peptidases and proteases — enzymes that cleave peptide bonds — which is why most peptides cannot survive oral ingestion intact and require injection or specialized formulation for therapeutic use. Fetse and colleagues, writing in Trends in Pharmacological Sciences in 2023, reviewed the chemical-modification strategies that make peptides more drug-like, including cyclization and substitution of D-amino acids, both of which resist enzymatic degradation. Drug developers have used this metabolic property to design modified peptides with more predictable half-lives, targeted delivery profiles, and in some cases reduced off-target effects versus unmodified peptide sequences.

Major Categories of Peptides

Peptides can be organized by source (endogenous, food-derived, or synthetic), by function (hormonal, antimicrobial, cosmetic, or oncological), or by regulatory status (FDA-approved drugs, compounded formulations, or research compounds). This article organizes by function, because functional classification is most useful for understanding what each class does and what evidence standard applies.

Hormonal and metabolic peptides

Peptide hormones regulate metabolism, appetite, and endocrine function. FDA-approved drugs in this category include semaglutide and liraglutide (GLP-1 receptor agonists) and tirzepatide (a dual GIP/GLP-1 receptor agonist). Lau and Dunn, writing in Bioorganic and Medicinal Chemistry in 2018, catalogued more than 60 approved peptide drugs and 150 in clinical development across the therapeutic spectrum, showing metabolic and hormonal peptides as a large and clinically established category.

Antimicrobial peptides

Antimicrobial peptides (AMPs) are part of the innate immune system, deployed by nearly all living organisms as a first-line defense against pathogens. They typically act by disrupting microbial membranes or modulating immune responses. Huan and colleagues, in a 2020 review in Frontiers in Microbiology, reviewed antimicrobial peptides as innate-immune molecules with broad applications across bacteria, fungi, parasites, and viruses. FDA-approved peptide-class antimicrobials include daptomycin (a cyclic lipopeptide approved for complicated skin and bloodstream infections) and the polymyxins (polymyxin B, colistin). Most novel antimicrobial peptides under investigation remain in preclinical or early clinical stages.

Collagen and structural peptides

Hydrolyzed collagen peptides are among the most widely available consumer peptide supplement categories. These are low-molecular-weight fragments derived from collagen protein through enzymatic hydrolysis or acid hydrolysis. Collagen peptide supplementation has been studied in multiple randomized trials for skin elasticity and joint tissue outcomes, though effect sizes and optimal dosing remain areas of active investigation. Barati and colleagues, in a 2020 review in Journal of Cosmetic Dermatology, reviewed collagen peptides and skin elasticity outcomes in a mechanistic systematic review. The same nutritional context distinguishes bone broth from collagen peptides in dietary applications.

Cosmetic peptides

Signal peptides, carrier peptides, and neurotransmitter-inhibitor peptides are used as topical cosmetic ingredients. Pintea and colleagues, in a 2025 review in Biomolecules, classified cosmetic peptide functional categories — signal, carrier, neurotransmitter-inhibitor, and enzyme-inhibitor types — each with distinct proposed mechanisms in the skin. These are regulated under FDA cosmetics law, not as drugs — physiological effect claims beyond appearance are not FDA-supported.

Research and investigational peptides

A large category of synthetic peptides has been studied in laboratory or animal models but is not FDA-approved for human use. Compounds such as BPC-157, TB-500, and MOTS-c are not FDA-approved for any human indication and are not under active, publicly disclosed Investigational New Drug (IND) programs for the uses typically discussed online. Human data for these compounds is primarily observational or preclinical; they do not carry the safety and efficacy record of FDA-approved peptide drugs. As of April 2026, BPC-157 is not FDA-approved for any human indication; FDA has placed BPC-157 on the Category 2 bulk drug substances list — substances FDA has identified as raising significant safety risks — which effectively bars it from 503A compounding. Available human data is primarily from limited observational reports; no adequate and well-controlled Phase 3 trials have been completed. This category carries the highest uncertainty for both safety and efficacy. Many non-approved compounds in this group are also sold online as peptide supplements, outside the regulatory framework that governs prescription products.

FDA-Approved Peptide Drugs: What Approval Means

FDA approval for a peptide drug requires completion of Phase 1 through Phase 3 clinical trials demonstrating safety and efficacy in the target population, manufacturing standards that ensure consistent identity and purity, and labeling that accurately describes the approved indication, dosage, and risk profile. Zhang and colleagues, in a 2020 review in the International Journal of Pharmaceutics, analyzed every peptide therapeutic approved by the FDA, EMA, and Japan's PMDA, cataloging dosage forms and delivery routes across the full approved landscape. As of April 2026, Li and colleagues, writing in Amino Acids in 2025, documented the continued growth of the approved peptide drug landscape, reflecting decades of clinical development across multiple disease areas. Selected FDA-approved examples include:

• Ozempic / Wegovy (semaglutide):
  • Active peptide: GLP-1 receptor agonist
  • Approved indication: Type 2 diabetes; chronic weight management
• Mounjaro (tirzepatide):
  • Active peptide: GIP/GLP-1 dual receptor agonist
  • Approved indication: Type 2 diabetes glycemic control
• Zepbound (tirzepatide):
  • Active peptide: GIP/GLP-1 dual receptor agonist
  • Approved indication: Chronic weight management; obstructive sleep apnea in adults with obesity (approved Dec 2024)
• Victoza / Saxenda (liraglutide):
  • Active peptide: GLP-1 receptor agonist
  • Approved indication: Type 2 diabetes; chronic weight management
• Forteo / Tymlos (teriparatide / abaloparatide):
  • Active peptide: PTH fragment / PTHrP analogue
  • Approved indication: Osteoporosis
• Lupron / Firmagon (leuprolide / degarelix):
  • Active peptide: GnRH agonist / antagonist
  • Approved indication: Prostate cancer; endometriosis; uterine fibroids
• Egrifta (tesamorelin):
  • Active peptide: GHRH analogue
  • Approved indication: HIV-associated lipodystrophy
• Natrecor (nesiritide):
  • Active peptide: B-type natriuretic peptide (BNP)
  • Approved indication: Acute decompensated heart failure
• Integrilin (eptifibatide):
  • Active peptide: Cyclic KGD-containing heptapeptide (GP IIb/IIIa inhibitor; derived from barbourin, a component of viper venom)
  • Approved indication: Acute coronary syndromes

This list illustrates the breadth of conditions addressed by FDA-approved peptide compounds — from metabolic disease to oncology to cardiovascular emergencies. Approval status and current labeled indications for any FDA-approved peptide drug can be verified at DailyMed, as indications and approvals change over time.

What "Safe" Means for Peptides — and What It Depends On

The answer to "are peptides safe?" is not one answer. It depends on which peptide, how it was evaluated, where it was obtained, and the biology of the individual using it.

FDA-approved peptides: known profiles from clinical trials

Approved peptide medications have defined safety profiles because they completed Phase 1 through Phase 3 trials with thousands of participants. For GLP-1 receptor agonists, Sattar and colleagues' 2021 meta-analysis in Lancet Diabetes and Endocrinology, pooling roughly 60,080 participants across eight cardiovascular outcomes trials, characterized the cardiovascular, mortality, and kidney outcomes of GLP-1 RAs, while Chiang and colleagues' 2025 systematic review in Gastroenterology documented gastrointestinal adverse effects (nausea, vomiting, diarrhea, and constipation) as the most commonly reported category. Cholelithiasis (gallstone formation) is a monitored risk with GLP-1 class agents. Thyroid C-cell effects observed in rodent carcinogenicity studies have been a subject of ongoing pharmacovigilance; the clinical significance of this signal in humans remains under evaluation. These risks are known, labeled, and monitored — a different safety posture than compounds without completed human trials.

Unregulated research peptides: evidence gaps and sourcing risks

Research peptides — compounds sold labeled "for research use only" without FDA approval — have a fundamentally different evidence profile. Most evidence is from rodent models with small sample sizes. No Phase 3 human trials exist for most compounds in this category. Manufacturing standards are not enforced for unregulated peptide products. Contamination at the synthesis stage is a documented concern: D'Hondt and colleagues, in a 2014 review in the Journal of Pharmaceutical and Biomedical Analysis, catalogued related impurities in peptide medicines as a quality-control problem that pharmaceutical-grade synthesis pipelines are designed to prevent, the kind of control absent in gray-market production. The risk is not theoretical: Nelson and colleagues published a 2012 case report in Clinical Toxicology in which a patient who self-administered online-purchased Melanotan II — an unregulated synthetic peptide — developed rhabdomyolysis and systemic toxicity following Melanotan II self-administration, requiring intensive care. Gentilucci and colleagues, in a 2006 review in Current Medicinal Chemistry, reviewed the therapeutic potential of peptides across multiple drug categories — but that potential is realized only when manufacturing, dosing, and administration are controlled. Products labeled "for research use only" are regulated as such only when actually used for non-human research; when sold or distributed in ways that manifest a therapeutic intent, FDA can treat them as unapproved new drugs under the intended use doctrine (21 CFR 201.128), which is why consumer purchase of RUO peptides for self-administration sits outside any legitimate regulatory pathway.

What affects safety at the individual level

Four factors determine peptide safety outcomes at the individual level regardless of compound. First, the regulatory status and manufacturing quality of the specific product. Second, the delivery route: oral peptide supplements have different absorption and risk profiles than injectable peptides, because most peptides are degraded in the gastrointestinal tract before reaching systemic circulation. Third, individual biology, including organ function, existing conditions, and concurrent medications. Fourth, whether baseline biomarkers were assessed before use — a factor that connects directly to the biomarker section below, because a baseline reading is the only way to interpret any subsequent biological change.

Which Biomarkers Are Relevant to Peptide Science?

Understanding baseline biology is the relevant starting point for anyone curious about peptide science, regardless of which compounds are under consideration. The mechanisms covered above — metabolic signaling, GH-axis activity, inflammatory pathways, renal clearance — each correspond to measurable bloodwork markers. Establishing these baselines provides objective reference points that make any subsequent biological change interpretable.

• Fasting insulin and glucose: Core metabolic markers for anyone exploring GLP-1 class peptides or metabolic health. Changes in these values are among the most studied outcomes in FDA-approved peptide drug trials. Baseline fasting insulin and glucose characterize insulin sensitivity before any metabolic intervention.
• HbA1c: Reflects average blood glucose over approximately 3 months. The primary endpoint in most metabolic peptide clinical trials, including the SUSTAIN, PIONEER, and STEP trial programs for GLP-1 class agents. A baseline HbA1c makes any subsequent metabolic change interpretable.
• IGF-1: Reflects growth hormone axis activity — the primary downstream marker for growth hormone-releasing peptides including tesamorelin and related GH-secretagogue compounds. Monitoring IGF-1 levels alongside any GH-related compound is standard clinical practice.
• CRP or hs-CRP: Systemic inflammatory marker relevant for peptides studied in anti-inflammatory or tissue-repair contexts. High-sensitivity CRP provides an objective reference point for tracking inflammatory burden over time.
• Lipid panel (total cholesterol, LDL, HDL, triglycerides): Cholelithiasis risk and lipid changes are monitored during GLP-1 agonist therapy. A pre-treatment baseline of triglycerides and related lipid markers supports interpretation of any changes.
• Kidney function (eGFR, creatinine): Renal clearance affects peptide metabolism and elimination. Impaired kidney function can alter pharmacokinetics of injectable peptides. An eGFR baseline is part of standard pre-treatment assessment for many FDA-approved compound protocols.
• Liver enzymes (ALT, AST): Hepatic function baseline. Standard pre-treatment assessment for any compound with hepatic processing. Alanine aminotransferase is a sensitive marker of hepatocellular stress.

Establishing a biomarker baseline before exploring any peptide protocol — dietary, pharmaceutical, or investigational — creates the objective reference points that make any subsequent data interpretable.

When These Questions Deserve Professional Attention

If the experience driving peptide research is a symptom — unexplained weight gain, persistent fatigue, poor metabolic function, or hormonal changes — that experience deserves a clinical evaluation before any compound is considered. The most appropriate first step is a primary care metabolic workup or endocrinology consultation for GH-axis concerns, beginning with bloodwork to establish objective baselines. A symptom is a signal that something in the biology deserves attention. A research peptide purchase is not a diagnostic tool.

The principle underlying that approach — understanding your biology before acting on it — is foundational to Superpower's approach to preventive health. In a space where evidence quality ranges from decades of large randomized controlled trials to single rodent studies, a measured baseline is the most reliable starting point for any clinical decision.

IMPORTANT SAFETY INFORMATION

This article discusses peptides as a broad category, including both FDA-approved medications and compounds that are not FDA-approved for any human use. Not all peptides discussed carry the same evidence base or safety profile. Superpower Health does not prescribe, sell, or facilitate access to peptide compounds that are not FDA-approved for human use.

FDA-approved peptide medications are prescription drugs that must be obtained through a licensed healthcare provider. Non-approved research peptides, often sold labeled "for research use only," are not regulated for human safety, efficacy, or manufacturing quality. Products purchased through unregulated channels may contain incorrect doses, contaminants, or misidentified compounds.

This content is not a substitute for medical advice, diagnosis, or treatment. If you are considering any peptide-based compound, consult a licensed healthcare provider before proceeding. Individual health conditions, medications, and organ function affect both suitability and response.

For information about FDA-approved peptide medications, visit dailymed.nlm.nih.gov. For FDA guidance on compounded peptides and bulk drug substance classifications, visit the FDA's compounding resource center.